At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.

Alphamers

Our science

Centauri Therapeutics is an immunotherapy company focused on infectious diseases. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases. Centauri holds an exclusive worldwide license to exploit the Alphamer® immunotherapeutics platform within the field of infectious diseases.

60%

of haematological cancer deaths are infection related2 Zembower, T.R. (2014). Epidemiology of Infections in Cancer Patients. In: Stosor, V., Zembower, T. (eds) Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol 161. Springer, Chamhttps://doi.org/10.1007/978-3-319-04220-6_2

$4.6bn

health care costs in the US to treat six antibiotic resistance threats3 https://www.cdc.gov/drugresistance/solutions-initiative/stories/partnership-estimates-healthcare-cost.html

Bacteria

Latest News and Articles

Centauri welcomes Dr Aisha Baba Dikwa

June 20, 2022

Centauri welcomes Dr Aisha Baba Dikwa who joins the scientific…

Read More
Aisha Baba Dikwa headshot

Centauri welcomes scientists to the team

June 1, 2022

Centauri is delighted to welcome Bailey Hairsine and Sana Mobeen…

Read More

Centauri opens lab at Alderley Park

May 1, 2022

Centauri Therapeutics has taken a laboratory lease on Alderley Park…

Read More
Arial shot of Centauri's lab at Alderley Park